FDA approves Sanofi lice treatment

Sklice lotion approved for patients ages 6 months and older

BRIDGEWATER, N.J. — The Food and Drug Administration has approved a head lice treatment made by Sanofi, the drug maker said.

Sanofi announced the approval of Sklice (ivermectin) lotion in the 0.5% strength for patients ages 6 months and older. According to Sanofi, head lice infest an estimated 6 to 12 million children ages 3 to 11 years and costs as much as $1 billion in lost school days and lost work for parents.

"The approval of Sklice lotion provides physicians and parents with a new treatment option for head lice, a condition that is notoriously frustrating to treat," Sanofi-Topaz general manager Kenneth Guito said. "Through a unique mode of action, Sklice lotion resolves most head lice infestations in one application and is very well-tolerated."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.